BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.
- University of Arkansas joins as tenth and final clinical site
- Pivotal FDA 510(k) trial to enrol at least 528 children across US sites
- Pilot study showed 83.7% sensitivity and 84.7% specificity, exceeding FDA benchmarks
- Trial to validate usability and diagnostic accuracy of BlinkLab Dx 1
- First patient testing expected to commence late March 2026
Completion of Clinical Network Marks Key Milestone
BlinkLab Limited (ASX:BB1), a digital health innovator developing AI-powered diagnostic tools, has announced the completion of its clinical trial network for a pivotal FDA 510(k) study. The University of Arkansas has been onboarded as the tenth and final clinical site, rounding out a geographically and demographically diverse group of leading US autism research centres. This milestone clears the way for the imminent commencement of patient enrolment and testing.
Building on Strong Pilot Data
The pivotal trial follows a successful pilot study involving 485 children, where BlinkLab’s flagship product, BlinkLab Dx 1, demonstrated diagnostic sensitivity of 83.7% and specificity of 84.7%. These results significantly exceeded the FDA’s agreed performance thresholds of 65% for both metrics, providing a strong foundation for the larger regulatory study. The upcoming trial will enrol a minimum of 528 children aged 2 to 11 years, further validating the technology’s accuracy and usability in diverse clinical settings.
Strategic Importance of the Clinical Sites
The network includes prestigious institutions such as Cincinnati Children’s Hospital, University of Pennsylvania, and Seattle Children’s Hospital, among others. The addition of the University of Arkansas, recognised for its high research activity and focus on digital health innovations, enhances the trial’s robustness. These sites not only contribute to rigorous data collection but also position BlinkLab to build strong relationships with key opinion leaders, which will be crucial for post-clearance commercialisation and clinical adoption.
Next Steps and Market Implications
With site initiation visits underway, BlinkLab and its contract research organisation are ensuring all locations meet regulatory and protocol standards before enrolling participants. The first patient testing is expected to begin by the end of March 2026. A successful pivotal study and subsequent FDA clearance would establish BlinkLab Dx 1 as a pioneering AI-enabled diagnostic aid for autism, potentially transforming early detection and intervention by addressing current challenges such as long waitlists and regional disparities in care.
Looking Ahead
As BlinkLab moves into this critical phase, the company is poised to redefine autism diagnostics through technology. The trial’s outcomes will be closely watched by investors, clinicians, and regulators alike, as they could herald a new era of digital health solutions in neurodevelopmental disorders.
Bottom Line?
BlinkLab’s completed clinical network sets the stage for a pivotal trial that could reshape autism diagnosis with AI.
Questions in the middle?
- How quickly will patient enrolment progress across the ten clinical sites?
- What interim data might BlinkLab release during the pivotal trial?
- How will FDA clearance impact BlinkLab’s commercial partnerships and market rollout?